Vir Biotechnology, Inc. (NASDAQ: VIR)

Vir Biotechnology, Inc., often referred to as Vir, operates in the biotechnology sector of the healthcare industry. Specifically, Vir is a commercial-stage immunology company dedicated to the development of treatments and preventions for serious infectious diseases. The company's mission is to create a world without infectious diseases, and it achieves this by focusing on four technology platforms that stimulate and enhance the immune system. These platforms include the antibody platform, T cell platform, innate immunity platform, and small interfering ribonucleic acid (siRNA) platform. Vir's competitive advantages lie in its ability to identify rare antibodies from survivors of infectious diseases, its expertise in developing T cell vaccines, and its ability to develop siRNA-based therapies.

The company generates revenue primarily through the development and commercialization of its product candidates. These candidates are focused on treating and preventing infectious diseases such as COVID-19, influenza, hepatitis B and D, HIV, and others. Vir's primary products include sotrovimab, a SARS-CoV-2-neutralizing monoclonal antibody, and VIR-221